Kingstown Capital Management L.P. Takes Position in Biotech Acquisition (NASDAQ:BIOT)

Kingstown Capital Management L.P. bought a new stake in shares of Biotech Acquisition (NASDAQ:BIOT) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 300,000 shares of the company’s stock, valued at approximately $2,916,000.

Other institutional investors have also made changes to their positions in the company. Berkley W R Corp purchased a new stake in shares of Biotech Acquisition during the 1st quarter valued at $477,000. Atalaya Capital Management LP purchased a new stake in shares of Biotech Acquisition during the 1st quarter valued at $5,402,000. Polar Asset Management Partners Inc. purchased a new stake in shares of Biotech Acquisition during the 1st quarter valued at $5,832,000. Blackstone Group Inc. purchased a new stake in Biotech Acquisition in the 1st quarter worth about $4,860,000. Finally, Jane Street Group LLC purchased a new stake in Biotech Acquisition in the 1st quarter worth about $1,027,000. 22.98% of the stock is owned by hedge funds and other institutional investors.

BIOT remained flat at $$9.67 during trading hours on Thursday. The company had a trading volume of 1,199 shares, compared to its average volume of 35,288. Biotech Acquisition has a 52 week low of $9.54 and a 52 week high of $9.95. The business’s 50-day moving average is $9.69.

Biotech Acquisition Profile

Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

See Also: How are the companies in the S&P 500 selected?

Want to see what other hedge funds are holding BIOT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biotech Acquisition (NASDAQ:BIOT).

Institutional Ownership by Quarter for Biotech Acquisition (NASDAQ:BIOT)

Receive News & Ratings for Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.